Relationship between IDH1 mutation and clinic pathologic features in human gliomas

doi:10.3877/cma.j.issn.2095-9141.2018.02.003

Abstract

Abstract:

Objective

To evaluate the frequency and Clinic Pathologic Features of isocitrate dehydrogenase 1 (IDH1) gene mutation in different pathological types and different WHO grades of glioma patients.

Methods

The frequency of IDH1 gene mutation was detected by immunohistochemistry in 76 patients with different pathological types and WHO grades of glioma specimens, and the pathological type, WHO grades and patient age of IDH1 gene mutation were analyzed.

Results

Among 76 glioma patients, IDH1 gene mutation was found in 37 patients, the total mutation rate was 48.68%. Mutation rates from high to low were as below: Diffuse Astrocytoma (71.43%), Anaplastic Oligoastrocytoma (71.43%), Oligodendroglioma (66.67%), Oligoastrocytoma (66.67%), Anaplastic Astrocytoma (63.64%), Glioblastoma (34.62%). Among Diffuse Astrocytoma, Oligoastrocytoma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma and Glioblastoma patients, IDH1 genotype patients were generally younger than wild-type ones,the difference was statistically significant.

Conclusion

The frequency of IDH1 gene mutation is high in WHO grade Ⅱ and Ⅲ gliomas. IDH1 gene mutation plays important role in the development and progression of glioma.

Key words: Glioma, Isocitrate dehydrogenase 1 gene, Mutation, Pathological type

Guowei Tan, Xi Chen, Jinli Sun, Sifang Chen, Jianfeng Guo, Zhanxiang Wang. Relationship between IDH1 mutation and clinic pathologic features in human gliomas[J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2018, 04(02): 73-76.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsjcswkdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9141.2018.02.003

https://zhsjcswkdzzz.cma-cmc.com.cn/EN/Y2018/V04/I02/73

Figures/Tables 2

References 15

[1]	Turkalp Z,Karamchandani J,Das S. IDH mutation in glioma: new insights and promises for the future[J]. JAMA Neurol, 2014, 71(10): 1319-1325.
[2]	Eckel-Passow JE,Lachance DH,Molinaro AM, et al. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors[J]. N Engl J Med, 2015, 372(26): 2499-508.
[3]	Pesenti C,Paganini L,Fontana L, et al. Mass spectrometry-based assay for the molecular diagnosis of glioma: concomitant detection of chromosome 1p/19q codeletion, and IDH1, IDH2, and TERT mutation status[J]. Oncotarget, 2017, 8(34): 57134-57148.
[4]	Mu L,Xu W,Li Q, et al. IDH1 R132H mutation is accompanied with malignant progression of paired primary-recurrent astrocytic tumours[J]. J Cancer, 2017, 8(14): 2704-2712.
[5]	Zhao S,Lin Y,Xu W, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha[J]. Science, 2009, 324(5924): 261-265.
[6]	Yalaza C,Ak H,Cagli MS, et al. R132H Mutation in IDH1 Gene is associated with increased tumor HIF1-alpha and serum VEGF levels in primary glioblastoma multiforme[J]. Ann Clin Lab Sci, 2017, 47(3): 362-364.
[7]	Yan H,Parsons DW,Jin G, et al. IDH1 and IDH2 mutations in gliomas[J]. N Engl J Med, 2009, 360(8): 765-773.
[8]	Turcan S,Rohle D,Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype[J]. Nature, 2012, 483(7390): 479-483.
[9]	Dimitrov L,Hong CS,Yang C, et al. New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma[J]. Int J Med Sci, 2015, 12(3): 201-213.
[10]	王国良,赛克,公方和,等.异柠檬酸脱氢酶1基因突变增加胶质瘤细胞对替莫唑胺的敏感性[J].中国临床神经外科杂志, 2014, 19(2): 95-98.
[11]	Chen N,Yu T,Gong J, et al. IDH1/2 gene hotspot mutations in central nervous system tumours: analysis of 922 Chinese patients[J]. Pathology, 2016, 48(7): 675-683.
[12]	Lopci E,Riva M,Olivari L, et al. Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma[J]. Eur J Nucl Med Mol Imaging, 2017, 44(7): 1155-1164.
[13]	Opoku-Darko M,Lang ST,Artindale J, et al. Surgical management of incidentally discovered diffusely infiltrating low-grade glioma[J]. J Neurosurg, 2017, Epub ahead of print.
[14]	Gessler F,Zappi J,Konczalla J, et al. Secondary glioblastoma: molecular and clinical factors that affect outcome after malignant progression of a lower grade tumor[J]. World Neurosurg, 2017, 102: 49-55.
[15]	Yang Y,Mao Q,Wang X, et al. An analysis of 170 glioma patients and systematic review to investigate the association between IDH-1 mutations and preoperative glioma-related epilepsy[J]. J Clin Neurosci, 2016, 31: 56-62.

病理类型	WHO分级	基因型	数量	平均年龄突变率（岁）(%)		t值	P值
毛细胞型星形细胞瘤	Ⅰ	突变型	0	-	0	-	-
毛细胞型星形细胞瘤	Ⅰ	野生型	3	23.3±3.2	0	-	-
弥漫性星形细胞瘤	Ⅱ	突变型	10	33.6±3.2	71.43	-3.297	0.002
弥漫性星形细胞瘤	Ⅱ	野生型	4	41.8±4.5	71.43	-3.297	0.002
少突胶质瘤	Ⅱ	突变型	2	35.0±1.4	66.67	-	-
少突胶质瘤	Ⅱ	野生型	1	37.0	66.67	-	-
少突星形细胞瘤	Ⅱ	突变型	4	33.3±2.8	66.67	-2.651	0.034
少突星形细胞瘤	Ⅱ	野生型	2	42.0±4.2	66.67	-2.651	0.034
室管膜瘤	Ⅱ	突变型	0	-	0	-	-
室管膜瘤	Ⅱ	野生型	4	35.5±3.1	0	-	-
节细胞胶质瘤	Ⅱ	突变型	0	-	0	-	-
节细胞胶质瘤	Ⅱ	野生型	2	41.5±2.1	0	-	-
间变型星形细胞瘤	Ⅲ	突变型	7	33.4±6.8	63.64	-4.922	0.002
间变型星形细胞瘤	Ⅲ	野生型	4	50.5±4.7	63.64	-4.922	0.002
间变型少突星形细胞瘤	Ⅲ	突变型	5	35.8±4.7	71.43	-3.903	0.019
间变型少突星形细胞瘤	Ⅲ	野生型	2	48.5±3.5	71.43	-3.903	0.019
胶质母细胞瘤	Ⅳ	突变型	9	41.7±5.0	34.62	-4.425	0.001
胶质母细胞瘤	Ⅳ	野生型	17	51.9±6.6	34.62	-4.425	0.001
原发性胶质母细胞瘤	Ⅳ	突变型	1	51	8.33	-	-
原发性胶质母细胞瘤	Ⅳ	野生型	11	53.2±7.8	8.33	-	-
继发性胶质母细胞瘤	Ⅳ	突变型	8	40.5±3.8	57.14	-5.223	0.001
继发性胶质母细胞瘤	Ⅳ	野生型	6	49.5±2.7	57.14	-5.223	0.001

病理类型	WHO分级	基因型	数量	平均年龄突变率（岁）(%)		t值	P值
毛细胞型星形细胞瘤	Ⅰ	突变型	0	-	0	-	-
毛细胞型星形细胞瘤	Ⅰ	野生型	3	23.3±3.2	0	-	-
弥漫性星形细胞瘤	Ⅱ	突变型	10	33.6±3.2	71.43	-3.297	0.002
弥漫性星形细胞瘤	Ⅱ	野生型	4	41.8±4.5	71.43	-3.297	0.002
少突胶质瘤	Ⅱ	突变型	2	35.0±1.4	66.67	-	-
少突胶质瘤	Ⅱ	野生型	1	37.0	66.67	-	-
少突星形细胞瘤	Ⅱ	突变型	4	33.3±2.8	66.67	-2.651	0.034
少突星形细胞瘤	Ⅱ	野生型	2	42.0±4.2	66.67	-2.651	0.034
室管膜瘤	Ⅱ	突变型	0	-	0	-	-
室管膜瘤	Ⅱ	野生型	4	35.5±3.1	0	-	-
节细胞胶质瘤	Ⅱ	突变型	0	-	0	-	-
节细胞胶质瘤	Ⅱ	野生型	2	41.5±2.1	0	-	-
间变型星形细胞瘤	Ⅲ	突变型	7	33.4±6.8	63.64	-4.922	0.002
间变型星形细胞瘤	Ⅲ	野生型	4	50.5±4.7	63.64	-4.922	0.002
间变型少突星形细胞瘤	Ⅲ	突变型	5	35.8±4.7	71.43	-3.903	0.019
间变型少突星形细胞瘤	Ⅲ	野生型	2	48.5±3.5	71.43	-3.903	0.019
胶质母细胞瘤	Ⅳ	突变型	9	41.7±5.0	34.62	-4.425	0.001
胶质母细胞瘤	Ⅳ	野生型	17	51.9±6.6	34.62	-4.425	0.001
原发性胶质母细胞瘤	Ⅳ	突变型	1	51	8.33	-	-
原发性胶质母细胞瘤	Ⅳ	野生型	11	53.2±7.8	8.33	-	-
继发性胶质母细胞瘤	Ⅳ	突变型	8	40.5±3.8	57.14	-5.223	0.001
继发性胶质母细胞瘤	Ⅳ	野生型	6	49.5±2.7	57.14	-5.223	0.001

病理类别/基因型	突变型	野生型	合计	突变率
原发性胶质母细胞瘤	1	11	12	8.33%
继发性胶质母细胞瘤	8	6	14	57.14%
χ²值	?	?	?	6.801
P值	?	?	?	0.009

病理类别/基因型	突变型	野生型	合计	突变率
原发性胶质母细胞瘤	1	11	12	8.33%
继发性胶质母细胞瘤	8	6	14	57.14%
χ²值	?	?	?	6.801
P值	?	?	?	0.009

Please choose a citation manager

Content to export